Search Results

You are looking at 1 - 10 of 437 items for :

  • "single agent" x
Clear All
Full access

Alison K. Conlin and Andrew D. Seidman

: a retrospective analysis based on individual patient data from six consecutive studies . Cancer 2005 ; 104 : 1742 – 1750 . 4. Carrick S Parker S Wilcken N . Single agent versus combination chemotherapy for metastatic breast cancer

Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma and Matthew J. Ellis

after 2 months of neratinib monotherapy. breast cancer responding to treatment with a single-agent, HER2-targeted drug. Furthermore, lapatinib would not have been an appropriate drug for our patient, because the HER2 L755S mutation alters the

Full access

Mary Cianfrocca and William J. Gradishar

treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women . J Clin Oncol 1998 ; 16 : 3439 – 3460 . 2. Carrick S Parker S Wilcken N . Single agent versus combination chemotherapy for

Full access

Ju Wang, Ye Zhang, Long Yuan, Lin Ren, Yi Zhang and Xiaowei Qi

. However, the optimal choice of first-line treatment is not still determined. Objective To compare the efficacy, safety and acceptability of single-agent PARP inhibitors for BRCA mutated HER2-negative metastatic or advanced breast cancer patients. Methods

Full access

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner and Henry S. Friedman

progression-free survival rates of 9% to 15%, and an overall survival of 22 to 26 weeks. 2 – 4 Two follow-up phase II studies became the basis of accelerated approval of single-agent bevacizumab for recurrent glioblastoma granted by the FDA in May 2009. The

Full access

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama and Manisha Palta

.5% received a different multiagent regimen (FOLFIRI [leucovorin/5-FU/irinotecan], FOLFIRINOX [leucovorin/5-FU/irinotecan/oxaliplatin], FOLFIRINOX + bevacizumab, FOLFOX + bevacizumab, or CAPEOX + bevacizumab). Of those who received single-agent chemotherapy, 63

Full access

Jeff Dang, Sang Chau, Jessy Delaisla, Divya Prakash and Andrew Hertler

stratified into 4 groups based on the type of treatment the patient received: single agent (n=66), PD-1/PDL-1 (n=157), platinum doublet (n=720), and platinum triplet (n=279). Chi-square and Kruskal-Wallis tests were performed as appropriate. Results: The

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith and Bhavana Konda

. Pathology revealed omentum with acute inflammation and abscess formation, with no evidence of malignancy in 13 lymph nodes. He recovered from surgery and was discontinued from the trial, but continued on single-agent dabrafenib due to the BRAF V600E

Full access

Amit Mahipal, Minsig Choi and Richard Kim

differences, but usually includes a fluoropyrimidine and a platinum agent. 13 In principle, combination chemotherapeutic regimens have been shown to improve survival compared with single-agent chemotherapy. A meta-analysis of 13 randomized trials demonstrated

Full access

Belqis El Ferjani, Sheenu Chandwani, Meita Hirschmann, Seydeh Dibaj, Emily Roarty, Jianjun Zhang, Waree Rinsurnogkawong, Jeff Lewis, Jack Lee, Jack A. Roth, Stephen Swisher, John V. Heymach, Thomas Burke and George R. Simon

.7%). Predominant reasons for not testing (63 pts) include not having available tissue (26 pts) or the test was not requested by the physician (31 pts). As of June 30, 2018, 38.5% of patients received immunotherapy as first-line therapy either as a single agent (18